key: cord-0890153-xou4hyga
authors: Wolters, Femke; Grünberg, Maria; Huber, Michael; Kessler, Harald H.; Prüller, Florian; Saleh, Lanja; Fébreau, Christine; Rahamat‐Langendoen, Janette; Thibault, Vincent; Melchers, Willem J. G.
title: European multicenter evaluation of Xpert® Xpress SARS‐CoV‐2/Flu/RSV test
date: 2021-06-06
journal: J Med Virol
DOI: 10.1002/jmv.27111
sha: d259e2d34277537e2788b78228d10bee786b2b39
doc_id: 890153
cord_uid: xou4hyga

Rapid diagnostics for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) are paramount for reducing the spread of the current pandemic. During additional seasonal epidemics with influenza A/B and respiratory syncytial virus (RSV), the clinical signs and symptoms cannot be distinguished easily from SARS‐CoV‐2. Therefore, a new assay combining four targets in the form of the new Xpert Xpress SARS‐CoV‐2/Flu/RSV assay was evaluated. The assay was compared to the Xpert Xpress SARS‐CoV‐2, Xpert Xpress Flu/RSV, Seegene Flu/RSV, influenza A/B r‐gene® and RSV/hMPV r‐gene®. A total of 295 nasopharyngeal and throat swabs were tested at four institutes throughout Europe including 72 samples positive for SARS‐CoV‐2, 65 for influenza A, 47 for influenza B, and 77 for RSV. The sensitivity of the new assay was above 95% for all targets, with the highest for SARS‐CoV‐2 (97.2%). The overall correlation of SARS‐CoV‐2 Ct values between Xpert Xpress SARS‐CoV‐2 assay and Xpert Xpress SARS‐CoV‐2/Flu/RSV assay was high. The agreement between Ct values above 30 showed the multiplex giving higher Ct values for SARS‐CoV‐2 on average than the singleplex assay. In conclusion, the new assay is a rapid and reliable alternative with less hands‐on time for the detection of not one, but four upper respiratory tract pathogens that may circulate at the same time.

are usually epidemic in Europe between November and April, may coincide with SARS-CoV-2. 3, 4 However, recent data from Australia show that those seasonal epidemics have been reduced during the SARS-CoV-2 pandemic, possibly as a result of isolation, restricted travel, and social distancing. 5 These respiratory viruses often show initial similar symptoms and cannot be differentiated on clinical presentation alone. However, they do require different isolation regimens, depending on the patient category, such as children, elderly, and the immunocompromised and the course of the diseases evolve differently according to each virus. [6] [7] [8] [9] Additionally, treatment options differ and surveillance of individual pathogens is relevant for public health decision making. 10, 11 To distinguish between four of the most common and clinically relevant seasonal airway pathogens and to be able to identify coinfections rapidly, a multiplex PCR, the Xpert Xpress SARS-CoV-2/Flu/RSV (multiplex) has been made available. 12, 13 The aim of this study was to evaluate this new multiplex PCR assay in a European multicenter setting. (Table 1 ) and stored at −80°C. SARS-Cov-2 was tested using Xpert Xpress SARS-CoV-2 (singleplex) and Xpert Xpress Flu/ RSV was used for the influenza A, B, and RSV positive samples. All samples underwent one freeze-thaw cycle before use in the validation of the SARS-CoV-2/Flu/RSV cartridge. Three samples included were co-infections. Two of the samples selected as influenza A positive were also RSV positive. One influenza A sample was also SARS-CoV-2 positive.

Left-over routine samples that had been obtained by a deep oropharyngeal swab with the Copan UTM™ (Copan) collection system and had been stored at −80°C were used for this study. All SARS-CoV-2 diagnostics were performed using the Xpress Xpress SARS-CoV-2 cartridge. Influenza A and B was tested using the Influenza A/ B R-GENE ® (bioMerieux SA) assay, RSV using the RSV/hMPV R-GENE ® (bioMerieux) assay. After extraction on the NicliSENS ® EMAG ® (bioMerieux) platform using the specific B protocol, amplification and detection were performed on the LC 480 II (Roche Diagnostics International Ltd.). Additionally, the CELL Control R-GENE ® (bioMerieux) kit was used for each sample. This assay includes an amplification premix detecting the human hypoxanthine phosphor-ribosyl transferase 1 gene and thus checking for the presence of human cells in the sample. Four samples included were coinfections, three were influenza A with RSV and one sample was influenza B with RSV. 

All samples were nasopharyngeal swabs collected in either TranSwab or eSwab medium and stored at −80°C until use. SARS-Cov-2 was tested using Xpert Xpress SARS-CoV-2 (singleplex). influenza A/B and RSV were tested using Seegene Allplex respiratory panel 1 (Eurobio) as recommended by the manufacturer. Seven included samples had coinfections as determined using the Seegene technique. Five samples were both influenza A and RSV positive, one sample was influenza B and RSV positive. One sample was influenza A and B positive. 

Xpress SARS-CoV-2/Flu/RSV, a PPA of 97.2% and NPA of 100% was observed compared to the reference assay performed at each institute (Table 2) . Two discrepant results were found; both samples tested T A B L E 2 Crosstables comparing Xpert Xpress SARS-CoV-2/Flu/RSV to the local method for SARS-COV-2 (i), influenza A (ii), influenza B (iii), and RSV(iv) detection Note: The green/orange background indicate discrepancies in the agreement between tests.

Abbreviations: NPA, negative percentage agreement; PPA, positive percentage agreement; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

positive with the reference method (Xpert Xpress SARS-CoV-2) but negative with the multiplex assay. Upon retesting, one sample tested negative with both assays ( Table 3) For the other targets, the results are presented in Two samples were discordant for detection of SARS-CoV-2 between the singleplex and multiplex assays. One of the samples was negative on retesting in the singleplex assay. This could either mean that freeze-thawing steps degraded the sample although this would be relatively surprising as an initial Ct value of 33 is relatively low.

Alternatively, misclassification or sample mix-up on initial testing before selection of the sample could be the cause. The other discordant case occurred in a sample with a low viral load, which could be near the limit of detection of the Xpert assay. This finding was similar for samples positive for influenza A, B, and RSV by Xpert Flu/ RSV but negative by Xpert SARS-CoV-2/Flu/RSV. These discordant cases could be caused by several freeze-thaw steps as these samples

were not retested using the reference method at the same time as testing with the multiplex assay.

In this study, throat and oropharyngeal swabs were used which are not part of the claim for the Xpert assay. However, these sample types are widely used in the field and are, in some countries, part of national guidelines, which is why it is important to assess the performance of the assay in this setting. Additionally, several types of transport medium were used for collection of samples. These were UTM/GLY medium, Copan UTM, and TranSwab or eSwab ( Table 1) .

Validation of transport medium was not performed in the current assay however all transport media has previously been validated for its use on the GeneXpert platform at the individual sites, where it has been used in different cartridges or on other reference platforms ( Table 1) F I G U R E 2 Bland-Altman plot with the difference in Ct value (multiplex-singleplex) on the Y-axis and average of single-and multiplex on the X-axis

Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity

Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus

SARS-CoV-2 detection in patients with influenza-like illness

Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review

Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses

Mortality in children from influenza and respiratory syncytial virus

Influenza-and respiratory syncytial virus-associated morbidity and mortality in the nursing home population

Morbidity profiles of patients consulting during influenza and respiratory syncytial virus active periods

Risk of mortality associated with respiratory syncytial virus and influenza infection in adults

Impact of rapid influenza testing at triage on management of febrile infants and young children

Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region

SARS-CoV-2 and influenza virus co-infection

Multicenter evaluation of the cepheid Xpert Xpress SARS-CoV-2 test

Simultaneous detection, subgrouping, and quantitation of respiratory syncytial virus A and B by real-time PCR

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Prospective and retrospective evaluation of the Cepheid Xpert ® Flu/RSV XC assay for rapid detection of influenza A, influenza B, and respiratory syncytial virus

Accurate PCR detection of Influenza A/B and respiratory syncytial viruses by use of Cepheid Xpert Flu+ RSV Xpress Assay in point-of-care settings: comparison to Prodesse ProFlu

Multi-center evaluation of cepheid xpert ® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic

The authors have declared that there are no conflict of interests. 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

http://orcid.org/0000-0002-6455-9802Janette Rahamat-Langendoen http://orcid.org/0000-0003-

Willem J. G. Melchers http://orcid.org/0000-0002-5446-2230